Clinical trial
A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the…
NCT00111189 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00111189 |
|---|---|
| Title | A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia. |
| Official title | A Randomized Double-blind Placebo-controlled Parallel Group Study Evaluating Paliperidone Palmitate in the Prevention of Recurrence in Patients With Schizophrenia. Placebo Consists of 20% Intralipid (200 mg/mL) Injectable Emulsion. |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | Janssen-Cilag International NV Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Placebo, Paliperidone Palmitate |
| Enrollment | 414 |
| Start date | Feb 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2008 |
| First posted | May 18, 2005 |
| Last update posted | Jun 20, 2014 |
| Countries | Costa Rica, Mexico, Romania, Russia, South Africa, South Korea, Taiwan, Ukraine, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: